The FDA will today convene an advisory committee to review and discuss the application submitted by Biogen Inc. for aducanumab for the treatment of early Alzheimer’s disease.
Though mixed opinions remain about whether the FDA should approve aducanumab at this time, the submission of a new treatment entity for Alzheimer’s disease is nonetheless good news and an important milestone. It has been nearly two decades since a new drug was approved for Alzheimer’s disease and no approved drug can effectively slow or stop the debilitating progression of this fatal neurodegenerative disease.
Regardless of the outcome of this specific submission, we hope that this marks the start of a new and exciting period in Alzheimer’s disease research — one with numerous promising candidate therapies achieve this milestone as well as approval and availability to the millions of people who so desperately need better treatment options.
